Cordlife GroupCLIFF 33 Gross Margin % is 57.94% as of Mar. 2026, which is 13% below its 10-year median of 66.56. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Cordlife Group ranks better than 56.92% on this metric.
Cordlife Group Ltd gross margin has been in long-term decline. The average rate of decline per year is -6.6%.
The historical rank and industry rank for Cordlife Group's Gross Margin % or its related term are showing as below:
CLIFF'
s Gross Margin % Range Over the Past 10 Years
Min: 41.72 Med: 66.56 Max: 69.67
Current: 58.14
During the past 13 years, the highestGross Margin % of Cordlife Group was 69.67%. The lowest was 41.72%. And the median was 66.56%.
CLIFF's Gross Margin % is ranked better than 56.92% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs CLIFF: 58.14
Cordlife Group had a gross margin of 57.94% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Cordlife Group was -6.60% per year.
Cordlife Group (OTCPK:CLIFF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cordlife Group had a gross margin of 57.94% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cordlife Group Gross Margin % Related Terms
Cordlife Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Cordlife Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cordlife Group (CLIFF) has a Gross Margin % of 57.94% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Cordlife Group and its competitors. This is 13% below median its historical median of 66.56. Over the past decade, Cordlife Group's Gross Margin % has ranged from 41.72 to 69.67. According to the industry distribution chart, Cordlife Group ranks #84 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 43.1%.
Is Cordlife Group's Gross Margin % too high?
Cordlife Group's current Gross Margin % of 57.94% is 13% below median its 10-year median of 66.56. Over the past 10 years, this metric has ranged from a low of 41.72 to a high of 69.67. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. Cordlife Group's value of 57.94% is 13.7% above this industry median. Based on the distribution chart, Cordlife Group ranks #84 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #84 out of 195 companies for Gross Margin %. This puts Cordlife Group in the upper half of its industry. The industry median Gross Margin % is 50.97. Cordlife Group's value of 57.94% is 13.7% above this benchmark. Historically, Cordlife Group's own Gross Margin % has ranged from 41.72 to 69.67 over the past decade. While the company's 10-year median is 66.56 vs. the industry median of 50.97, Cordlife Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current Gross Margin % of 57.94% is 13.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current Gross Margin % is 57.94%, which is 13% below median its own 10-year median of 66.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current Gross Margin % is 57.94%, which is 13% below median its 10-year median of 66.56 and 13.7% above the Medical Diagnostics & Research industry median of 50.97. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Gross Margin % is 57.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
Gross Margin %: 57.94% (13% below median its 10-year median of 66.56)
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
Industry Position: 13.7% above the Medical Diagnostics & Research median (#84 of 195)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
